{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:04:05Z","timestamp":1783706645329,"version":"3.55.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12072-026-11050-2","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:27:15Z","timestamp":1771936035000},"page":"240-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Taiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablation"],"prefix":"10.1007","volume":"20","author":[{"given":"Ching-Wei","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yu","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Feng","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jer","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Yung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih Horng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Cheng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chung","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-I.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"11050_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.02.006","author":"A Vogel","year":"2025","unstructured":"Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025. https:\/\/doi.org\/10.1016\/j.annonc.2025.02.006","journal-title":"Ann Oncol"},{"issue":"1","key":"11050_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7(1): 6","journal-title":"Nat Rev Dis Prim"},{"issue":"4","key":"11050_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet JM, Pinyol R, Yarchoan M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024;21(4):294\u2013311","journal-title":"Nat Rev Clin Oncol"},{"key":"11050_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1159\/000544976","volume":"14","author":"S Shiina","year":"2025","unstructured":"Shiina S, Tateishi R, Choi JI, et al. Asian conference on tumor ablation guidelines for hepatocellular carcinoma. Liver Cancer. 2025;14:651\u2013678","journal-title":"Liver Cancer."},{"issue":"2","key":"11050_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the L","year":"2025","unstructured":"European Association for the Study of the L. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u2013374","journal-title":"J Hepatol"},{"issue":"2","key":"11050_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.17998\/jlc.2024.08.04","volume":"24","author":"S Han","year":"2024","unstructured":"Han S, Sung PS, Park SY, et al. Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendation of the Korean Liver Cancer Association. J Liver Cancer. 2024;24(2):131\u2013144","journal-title":"J Liver Cancer"},{"key":"11050_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194763","author":"Y Minami","year":"2023","unstructured":"Minami Y, Aoki T, Hagiwara S, Kudo M. Tips for preparing and practicing thermal ablation therapy of hepatocellular carcinoma. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15194763","journal-title":"Cancers (Basel)"},{"issue":"7650","key":"11050_CR8","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u2013926","journal-title":"BMJ"},{"issue":"2","key":"11050_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2023.04.021","volume":"79","author":"European Association for the Study of the L","year":"2023","unstructured":"European Association for the Study of the L. EASL Clinical Practice Guidelines on acute-on-chronic liver failure. J Hepatol. 2023;79(2):461\u2013491","journal-title":"J Hepatol"},{"issue":"7454","key":"11050_CR10","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490","journal-title":"BMJ"},{"key":"11050_CR11","doi-asserted-by":"publisher","DOI":"10.1159\/000546765","author":"MS Wu","year":"2025","unstructured":"Wu MS, Kao WY, Chiang MF, et al. Consensus guideline of ablation for metastatic liver tumors by Taiwan Academy of Tumor Ablation. Liver Cancer. 2025. https:\/\/doi.org\/10.1159\/000546765","journal-title":"Liver Cancer"},{"issue":"4","key":"11050_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2468-1253(24)00247-4","volume":"10","author":"BY Zhong","year":"2025","unstructured":"Zhong BY, Fan W, Guan JJ, et al. Combination locoregional and systemic therapies in hepatocellular carcinoma. Lancet Gastroenterol Hepatol. 2025;10(4):369\u2013386","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"11050_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000521665","volume":"11","author":"T Takayama","year":"2022","unstructured":"Takayama T, Hasegawa K, Izumi N, et al. Surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF trial). Liver Cancer. 2022;11(3):209\u2013218","journal-title":"Liver Cancer"},{"issue":"13","key":"11050_CR14","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/bjs.10677","volume":"104","author":"KKC Ng","year":"2017","unstructured":"Ng KKC, Chok KSH, Chan ACY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg. 2017;104(13):1775\u20131784","journal-title":"Br J Surg"},{"issue":"4","key":"11050_CR15","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","volume":"57","author":"K Feng","year":"2012","unstructured":"Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57(4):794\u2013802","journal-title":"J Hepatol"},{"issue":"4","key":"11050_CR16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/SLA.0000000000004350","volume":"273","author":"SW Shin","year":"2021","unstructured":"Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver resection versus local ablation therapies for hepatocellular carcinoma within the Milan Criteria: a systematic review and meta-analysis. Ann Surg. 2021;273(4):656\u2013666","journal-title":"Ann Surg"},{"issue":"6","key":"11050_CR17","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u20131965","journal-title":"Hepatology"},{"issue":"6","key":"11050_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1159\/000517393","volume":"10","author":"YW Hung","year":"2021","unstructured":"Hung YW, Lee IC, Chi CT, et al. Redefining tumor burden in patients with intermediate-stage hepatocellular carcinoma: the seven-eleven criteria. Liver Cancer. 2021;10(6):629\u2013640","journal-title":"Liver Cancer"},{"issue":"1","key":"11050_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1055\/s-0033-1333656","volume":"30","author":"MC Higgins","year":"2013","unstructured":"Higgins MC, Soulen MC. Combining locoregional therapies in the treatment of hepatocellular carcinoma. Semin Intervent Radiol. 2013;30(1):74\u201381","journal-title":"Semin Intervent Radiol"},{"issue":"3","key":"11050_CR20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1148\/radiol.13130387","volume":"269","author":"Y Takuma","year":"2013","unstructured":"Takuma Y, Takabatake H, Morimoto Y, et al. Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria. Radiology. 2013;269(3):927\u2013937","journal-title":"Radiology"},{"issue":"4","key":"11050_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2012.42.9936","volume":"31","author":"ZW Peng","year":"2013","unstructured":"Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31(4):426\u2013432","journal-title":"J Clin Oncol"},{"issue":"9","key":"11050_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.26992","volume":"4","author":"YJ Zhang","year":"2021","unstructured":"Zhang YJ, Chen MS, Chen Y, Lau WY, Peng Z. Long-term outcomes of transcatheter arterial chemoembolization combined with radiofrequency ablation as an initial treatment for early-stage hepatocellular carcinoma. JAMA Netw Open. 2021;4(9): e2126992","journal-title":"JAMA Netw Open"},{"issue":"1","key":"11050_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/02656736.2022.2048095","volume":"39","author":"Y Yang","year":"2022","unstructured":"Yang Y, Yu H, Qi L, et al. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis. Int J Hyperthermia. 2022;39(1):455\u2013465","journal-title":"Int J Hyperthermia"},{"key":"11050_CR24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2147\/JHC.S342266","volume":"9","author":"D Papaconstantinou","year":"2022","unstructured":"Papaconstantinou D, Tsilimigras DI, Pawlik TM. Recurrent hepatocellular carcinoma: patterns, detection, staging and treatment. J Hepatocell Carcinoma. 2022;9:947\u2013957","journal-title":"J Hepatocell Carcinoma"},{"issue":"1","key":"11050_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/hep.23965","volume":"53","author":"S Rossi","year":"2011","unstructured":"Rossi S, Ravetta V, Rosa L, et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology. 2011;53(1):136\u2013147","journal-title":"Hepatology"},{"key":"11050_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215398","author":"N Machairas","year":"2022","unstructured":"Machairas N, Papaconstantinou D, Dorovinis P, et al. Meta-analysis of repeat hepatectomy versus radiofrequency ablation for recurrence of hepatocellular carcinoma. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14215398","journal-title":"Cancers (Basel)"},{"issue":"6","key":"11050_CR27","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.cgh.2022.08.023","volume":"21","author":"AC Huang","year":"2023","unstructured":"Huang AC, Dodge JL, Yao FY, Mehta N. National experience on waitlist outcomes for down-staging of hepatocellular carcinoma: high dropout rate in all-comers. Clin Gastroenterol Hepatol. 2023;21(6):1581\u20131589","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"11050_CR28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/hep.29485","volume":"67","author":"L Kulik","year":"2018","unstructured":"Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67(1):381\u2013400","journal-title":"Hepatology"},{"issue":"7","key":"11050_CR29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/lt.25492","volume":"25","author":"Q Lai","year":"2019","unstructured":"Lai Q, Vitale A, Iesari S, et al. The intention-to-treat effect of bridging treatments in the setting of Milan criteria-in patients waiting for liver transplantation. Liver Transpl. 2019;25(7):1023\u20131033","journal-title":"Liver Transpl"},{"issue":"4","key":"11050_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000529574","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo M, Aoki T, Ueshima K, et al. Achievement of complete response and drug-free status by Atezolizumab plus Bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. Liver Cancer. 2023;12(4):321\u2013338","journal-title":"Liver Cancer"},{"issue":"11","key":"11050_CR31","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1245\/s10434-008-0071-3","volume":"15","author":"JT Heckman","year":"2008","unstructured":"Heckman JT, Devera MB, Marsh JW, et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol. 2008;15(11):3169\u20133177","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"11050_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1148\/radiol.2019181991","volume":"293","author":"F Shi","year":"2019","unstructured":"Shi F, Wu M, Lian SS, et al. Radiofrequency ablation following downstaging of hepatocellular carcinoma by using transarterial chemoembolization: long-term outcomes. Radiology. 2019;293(3):707\u2013715","journal-title":"Radiology"},{"issue":"5","key":"11050_CR33","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1159\/000536549","volume":"13","author":"TH Liu","year":"2024","unstructured":"Liu TH, Chen SC, Rau KM, et al. Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma- with emphasis on locoregional therapy for oligoprogression. Liver Cancer. 2024;13(5):509\u2013521","journal-title":"Liver Cancer"},{"issue":"8","key":"11050_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/CJI.0000000000000333","volume":"43","author":"F Comito","year":"2020","unstructured":"Comito F, Leslie I, Boos L, et al. Oligoprogression after checkpoint inhibition in metastatic melanoma treated with locoregional therapy: a single-center retrospective analysis. J Immunother. 2020;43(8):250\u2013255","journal-title":"J Immunother"},{"key":"11050_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.lungcan.2021.09.019","volume":"161","author":"PJM Joosten","year":"2021","unstructured":"Joosten PJM, de Langen AJ, van der Noort V, et al. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer. Lung Cancer. 2021;161:141\u2013151","journal-title":"Lung Cancer"},{"issue":"1","key":"11050_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19251-y","volume":"8","author":"SY Ho","year":"2018","unstructured":"Ho SY, Liu PH, Hsu CY, et al. Prognostic performance of ten liver function models in patients with hepatocellular carcinoma undergoing radiofrequency ablation. Sci Rep. 2018;8(1): 843","journal-title":"Sci Rep"},{"issue":"1","key":"11050_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.14366\/usg.22041","volume":"42","author":"MG Jo","year":"2023","unstructured":"Jo MG, Lee MW, Ahn S, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma in a recent cohort at a tertiary cancer center: incidence and factors associated with major complications and unexpected hospitalization events. Ultrasonography. 2023;42(1):41\u201353","journal-title":"Ultrasonography"},{"issue":"1","key":"11050_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/JCMA.0000000000000001","volume":"82","author":"PC Chen","year":"2019","unstructured":"Chen PC, Chiu NC, Su CW, et al. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. J Chin Med Assoc. 2019;82(1):2\u201310","journal-title":"J Chin Med Assoc"},{"key":"11050_CR39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jhep.2025.03.017","volume":"83","author":"European Association for the Study of the L","year":"2025","unstructured":"European Association for the Study of the L. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis. J Hepatol. 2025;83:453\u2013501","journal-title":"J Hepatol"},{"issue":"15","key":"11050_CR40","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521\u20131531","journal-title":"N Engl J Med"},{"issue":"18","key":"11050_CR41","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/2012.jama.11975","volume":"308","author":"CY Wu","year":"2012","unstructured":"Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308(18):1906\u20131914","journal-title":"JAMA"},{"issue":"10179","key":"11050_CR42","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453\u20131464","journal-title":"Lancet"},{"key":"11050_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.08.030","author":"GN Ioannou","year":"2017","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017. https:\/\/doi.org\/10.1016\/j.jhep.2017.08.030","journal-title":"J Hepatol"},{"issue":"3","key":"11050_CR44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/gutjnl-2020-323663","volume":"71","author":"V Sapena","year":"2022","unstructured":"Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut. 2022;71(3):593\u2013604","journal-title":"Gut"},{"issue":"6","key":"11050_CR45","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jfma.2020.04.003","volume":"119","author":"ML Yu","year":"2020","unstructured":"Yu ML, Chen PJ, Dai CY, et al. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. J Formos Med Assoc. 2020;119(6):1019\u20131040","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"11050_CR46","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12072-019-09988-7","volume":"13","author":"T Kanda","year":"2019","unstructured":"Kanda T, Lau GKK, Wei L, et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int. 2019;13(6):649\u2013661","journal-title":"Hepatol Int"},{"issue":"5","key":"11050_CR47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","volume":"10","author":"M Omata","year":"2016","unstructured":"Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10(5):702\u2013726","journal-title":"Hepatol Int"},{"issue":"7","key":"11050_CR48","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jfma.2020.04.002","volume":"119","author":"ML Yu","year":"2020","unstructured":"Yu ML, Chen PJ, Dai CY, et al. 2020 Taiwan consensus statement on the management of hepatitis C: part (II) special populations. J Formos Med Assoc. 2020;119(7):1135\u20131157","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"11050_CR49","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1053\/j.gastro.2019.07.040","volume":"157","author":"AG Singal","year":"2019","unstructured":"Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology. 2019;157(5):1253-1263e1252","journal-title":"Gastroenterology"},{"issue":"7","key":"11050_CR50","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/apt.18199","volume":"60","author":"KC Wu","year":"2024","unstructured":"Wu KC, Lee IC, Chi CT, et al. Impact of HCV eradication on recurrence pattern and long-term outcomes in patients with HCV-related hepatocellular carcinoma undergoing radiofrequency ablation. Aliment Pharmacol Ther. 2024;60(7):940\u2013952","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"11050_CR51","first-page":"11","volume":"1","author":"MC Wu","year":"2012","unstructured":"Wu MC, Tang ZY, Ye SL, et al. Expert consensus on local ablation therapies for primary liver cancer. Chin Clin Oncol. 2012;1(1):11","journal-title":"Chin Clin Oncol"},{"issue":"3","key":"11050_CR52","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7326\/M14-1589","volume":"162","author":"RM Kaufman","year":"2015","unstructured":"Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205\u2013213","journal-title":"Ann Intern Med"},{"issue":"4","key":"11050_CR53","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3350\/cmh.2022.0294","volume":"28","author":"Korean Liver Cancer A, National Cancer Center K","year":"2022","unstructured":"Korean Liver Cancer A, National Cancer Center K. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(4):583\u2013705","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"11050_CR54","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000530495","volume":"12","author":"J Zhou","year":"2023","unstructured":"Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). Liver Cancer. 2023;12(5):405\u2013444","journal-title":"Liver Cancer."},{"issue":"3","key":"11050_CR55","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.22742","volume":"49","author":"DC Rockey","year":"2009","unstructured":"Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver D. Liver biopsy Hepatology. 2009;49(3):1017\u20131044","journal-title":"Liver biopsy Hepatology"},{"issue":"1","key":"11050_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-79416-w","volume":"14","author":"F Zhao","year":"2024","unstructured":"Zhao F, Zhang T, Yang Q, Zhang X, Yang F, Qian N. Safety of local thermal ablation in hepatocellular carcinoma patients with cirrhosis and severe thrombocytopenia. Sci Rep. 2024;14(1): 28350","journal-title":"Sci Rep"},{"issue":"12","key":"11050_CR57","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1097\/01.RVI.0000099532.29957.4F","volume":"14","author":"T Shibata","year":"2003","unstructured":"Shibata T, Yamamoto Y, Yamamoto N, et al. Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol. 2003;14(12):1535\u20131542","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"11050_CR58","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2214\/ajr.181.3.1810695","volume":"181","author":"T de Baere","year":"2003","unstructured":"de Baere T, Risse O, Kuoch V, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol. 2003;181(3):695\u2013700","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"11050_CR59","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jvir.2011.12.025","volume":"23","author":"R Hoffmann","year":"2012","unstructured":"Hoffmann R, Rempp H, Schmidt D, Pereira PL, Claussen CD, Clasen S. Prolonged antibiotic prophylaxis in patients with bilioenteric anastomosis undergoing percutaneous radiofrequency ablation. J Vasc Interv Radiol. 2012;23(4):545\u2013551","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"11050_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-024-02376-5","volume":"24","author":"F Liu","year":"2024","unstructured":"Liu F, Tan L, Luo L, Pan JJ. Comparison of laparoscopic hepatectomy and percutaneous radiofrequency ablation for the treatment of small hepatocellular carcinoma: a meta-analysis. BMC Surg. 2024;24(1): 83","journal-title":"BMC Surg"},{"issue":"5","key":"11050_CR61","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1097\/JS9.0000000000002302","volume":"111","author":"M Yang","year":"2025","unstructured":"Yang M, Li G, Chen K, Wu Y, Sun T, Wang W. Liver resection versus radiofrequency ablation for solitary small hepatocellular carcinoma measuring <\/=3 cm: a systematic review and meta-analysis. Int J Surg. 2025;111(5):3456\u20133466","journal-title":"Int J Surg"},{"issue":"5","key":"11050_CR62","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1007\/s00330-019-06609-7","volume":"30","author":"G Laimer","year":"2020","unstructured":"Laimer G, Schullian P, Jaschke N, et al. Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation. Eur Radiol. 2020;30(5):2463\u20132472","journal-title":"Eur Radiol"},{"key":"11050_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejro.2023.100501","volume":"11","author":"P Hendriks","year":"2023","unstructured":"Hendriks P, Boel F, Oosterveer TT, et al. Ablation margin quantification after thermal ablation of malignant liver tumors: How to optimize the procedure? A systematic review of the available evidence. Eur J Radiol Open. 2023;11: 100501","journal-title":"Eur J Radiol Open"},{"issue":"5","key":"11050_CR64","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jfma.2017.09.007","volume":"117","author":"Surveillance Group, Diagnosis Group, Staging Group","year":"2018","unstructured":"Surveillance Group, Diagnosis Group, Staging Group, et al. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117(5):381\u2013403","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"11050_CR65","doi-asserted-by":"publisher","first-page":"8649","DOI":"10.1007\/s00330-021-07729-9","volume":"31","author":"CC Lin","year":"2021","unstructured":"Lin CC, Lui KW, Chen WT, et al. Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma. Eur Radiol. 2021;31(11):8649\u20138661","journal-title":"Eur Radiol"},{"issue":"8","key":"11050_CR66","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3348\/kjr.2023.0423","volume":"24","author":"S Han","year":"2023","unstructured":"Han S, Lee MW, Lee YJ, Hong HP, Lee DH, Lee JM. No-touch radiofrequency ablation for early hepatocellular carcinoma: 2023 Korean Society of Image-Guided Tumor Ablation Guidelines. Korean J Radiol. 2023;24(8):719\u2013728","journal-title":"Korean J Radiol"},{"issue":"1","key":"11050_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101269","volume":"7","author":"K Sugimoto","year":"2025","unstructured":"Sugimoto K, Imajo K, Kuroda H, et al. Microwave ablation vs. single-needle radiofrequency ablation for the treatment of HCC up to 4 cm: a randomized-controlled trial. JHEP Rep. 2025;7(1): 101269","journal-title":"JHEP Rep"},{"issue":"1","key":"11050_CR68","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41598-021-03802-x","volume":"12","author":"A Radosevic","year":"2022","unstructured":"Radosevic A, Quesada R, Serlavos C, et al. Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial. Sci Rep. 2022;12(1):316","journal-title":"Sci Rep"},{"issue":"3","key":"11050_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102300","volume":"48","author":"E Ndhlovu","year":"2024","unstructured":"Ndhlovu E, Zhang BX, Chen XP, Zhu P. Thermal ablation for hepatic tumors in high-risk locations. Clin Res Hepatol Gastroenterol. 2024;48(3): 102300","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"11050_CR70","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/hep.21164","volume":"43","author":"T Teratani","year":"2006","unstructured":"Teratani T, Yoshida H, Shiina S, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 2006;43(5):1101\u20131108","journal-title":"Hepatology"},{"issue":"3","key":"11050_CR71","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3109\/02656736.2012.661915","volume":"28","author":"N Liu","year":"2012","unstructured":"Liu N, Gao J, Liu Y, et al. Determining a minimal safe distance to prevent thermal injury to intrahepatic bile ducts in radiofrequency ablation of the liver: a study in dogs. Int J Hyperthermia. 2012;28(3):210\u2013217","journal-title":"Int J Hyperthermia"},{"issue":"6","key":"11050_CR72","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2214\/AJR.14.13788","volume":"204","author":"ER Felker","year":"2015","unstructured":"Felker ER, Lee-Felker SA, Ajwichai K, et al. Intraductal cooling via a nasobiliary tube during radiofrequency ablation of central liver tumors reduces biliary injuries. AJR Am J Roentgenol. 2015;204(6):1329\u20131335","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"11050_CR73","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00261-018-1831-6","volume":"44","author":"YC Hsieh","year":"2019","unstructured":"Hsieh YC, Limquiaco JL, Lin CC, Chen WT, Lin SM. Radiofrequency ablation following artificial ascites and pleural effusion creation may improve outcomes for hepatocellular carcinoma in high-risk locations. Abdom Radiol (NY). 2019;44(3):1141\u20131151","journal-title":"Abdom Radiol (NY)"},{"issue":"12","key":"11050_CR74","doi-asserted-by":"publisher","first-page":"e641","DOI":"10.1016\/j.crad.2013.07.008","volume":"68","author":"TW Kang","year":"2013","unstructured":"Kang TW, Lim HK, Lee MW, Kim YS, Choi D, Rhim H. First-line radiofrequency ablation with or without artificial ascites for hepatocellular carcinomas in a subcapsular location: local control rate and risk of peritoneal seeding at long-term follow-up. Clin Radiol. 2013;68(12):e641-651","journal-title":"Clin Radiol"},{"issue":"10","key":"11050_CR75","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/bjs.5374","volume":"93","author":"Y Kondo","year":"2006","unstructured":"Kondo Y, Yoshida H, Shiina S, Tateishi R, Teratani T, Omata M. Artificial ascites technique for percutaneous radiofrequency ablation of liver cancer adjacent to the gastrointestinal tract. Br J Surg. 2006;93(10):1277\u20131282","journal-title":"Br J Surg"},{"issue":"3","key":"11050_CR76","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00261-008-9408-4","volume":"34","author":"H Rhim","year":"2009","unstructured":"Rhim H, Lim HK. Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: the value of artificial ascites. Abdom Imaging. 2009;34(3):371\u2013380","journal-title":"Abdom Imaging"},{"issue":"4","key":"11050_CR77","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s12072-015-9639-8","volume":"9","author":"CC Wang","year":"2015","unstructured":"Wang CC, Kao JH. Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma. Hepatol Int. 2015;9(4):514\u2013519","journal-title":"Hepatol Int"},{"issue":"1","key":"11050_CR78","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1148\/radiol.14140690","volume":"275","author":"YJ Lee","year":"2015","unstructured":"Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology. 2015;275(1):97\u2013109","journal-title":"Radiology"},{"issue":"1","key":"11050_CR79","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hep.29487","volume":"67","author":"LR Roberts","year":"2018","unstructured":"Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology. 2018;67(1):401\u2013421","journal-title":"Hepatology"},{"issue":"5","key":"11050_CR80","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000537686","volume":"13","author":"W Teng","year":"2024","unstructured":"Teng W, Wang HW, Lin SM, Diagnosis G, Systemic Therapy Group of T. Management consensus guidelines for hepatocellular carcinoma: 2023 update on surveillance, diagnosis, systemic treatment, and posttreatment monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Liver Cancer. 2024;13(5):468\u2013486","journal-title":"Liver Cancer"},{"issue":"4","key":"11050_CR81","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317\u2013370","journal-title":"Hepatol Int"},{"issue":"9","key":"11050_CR82","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3348\/kjr.2024.0550","volume":"25","author":"S Han","year":"2024","unstructured":"Han S, Sung PS, Park SY, et al. Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendations of the Korean Liver Cancer Association. Korean J Radiol. 2024;25(9):773\u2013787","journal-title":"Korean J Radiol"},{"issue":"2","key":"11050_CR83","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jhep.2016.09.003","volume":"66","author":"SJ Ahn","year":"2017","unstructured":"Ahn SJ, Lee JM, Lee DH, et al. Real-time US-CT\/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. J Hepatol. 2017;66(2):347\u2013354","journal-title":"J Hepatol"},{"issue":"2","key":"11050_CR84","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1148\/radiol.2017162382","volume":"285","author":"WY Kao","year":"2017","unstructured":"Kao WY, Su CW, Chiou YY, et al. Hepatocellular carcinoma: nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation. Radiology. 2017;285(2):670\u2013680","journal-title":"Radiology"},{"issue":"5","key":"11050_CR85","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s12072-021-10236-0","volume":"15","author":"CH Wu","year":"2021","unstructured":"Wu CH, Liang PC, Su TH, et al. Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma. Hepatol Int. 2021;15(5):1247\u20131257","journal-title":"Hepatol Int"},{"key":"11050_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030409","author":"H Li","year":"2025","unstructured":"Li H, Vogl TJ, Chen KA, Adwan H. A comparison of the efficacy and safety of US-, CT-, and MR-guided radiofrequency and microwave ablation for HCC: a systematic review and network meta-analysis. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17030409","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11050_CR87","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3350\/cmh.2014.20.1.61","volume":"20","author":"JH Min","year":"2014","unstructured":"Min JH, Lim HK, Lim S, et al. Radiofrequency ablation of very-early-stage hepatocellular carcinoma inconspicuous on fusion imaging with B-mode US: value of fusion imaging with contrast-enhanced US. Clin Mol Hepatol. 2014;20(1):61\u201370","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"11050_CR88","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s00261-017-1075-x","volume":"42","author":"DI Cha","year":"2017","unstructured":"Cha DI, Lee MW, Song KD, et al. A prospective comparison between auto-registration and manual registration of real-time ultrasound with MR images for percutaneous ablation or biopsy of hepatic lesions. Abdom Radiol. 2017;42(6):1799\u20131808","journal-title":"Abdom Radiol"},{"issue":"6","key":"11050_CR89","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1007\/s00261-024-04724-8","volume":"50","author":"Q Zeng","year":"2025","unstructured":"Zeng Q, Yan R, Zhang L, et al. Intelligent automatic registration: is it feasible and efficient for application of ultrasound fusion imaging in liver? Abdom Radiol (NY). 2025;50(6):2512\u20132521","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"11050_CR90","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.1055\/s-0043-123931","volume":"4","author":"CF Dietrich","year":"2018","unstructured":"Dietrich CF, Averkiou M, Nielsen MB, et al. How to perform contrast-enhanced ultrasound (CEUS). Ultrasound Int Open. 2018;4(1):E2\u2013E15","journal-title":"Ultrasound Int Open"},{"issue":"1","key":"11050_CR91","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12880-024-01508-w","volume":"24","author":"YB Lu","year":"2024","unstructured":"Lu YB, Huang YN, Weng YC, et al. Contrast-enhanced ultrasonography guidance avoids US-CT\/MR fusion error for percutaneous radiofrequency ablation of hepatocellular carcinoma. BMC Med Imaging. 2024;24(1):323","journal-title":"BMC Med Imaging"},{"issue":"1","key":"11050_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-023-00650-y","volume":"24","author":"Y Lee","year":"2024","unstructured":"Lee Y, Yoon JH, Han S, Joo I, Lee JM. Contrast-enhanced ultrasonography-CT\/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: improving feasibility and therapeutic outcome. Cancer Imaging. 2024;24(1): 4","journal-title":"Cancer Imaging"},{"issue":"1","key":"11050_CR93","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1080\/02656736.2021.1943545","volume":"38","author":"JH Gu","year":"2021","unstructured":"Gu JH, Zhao QY, He C, Ye ZD, Xu M, Jiang TA. Fusion imaging-guided radiofrequency ablation for residual hepatocellular carcinoma invisible on ultrasound after transcatheter arterial chemoembolization. Int J Hyperthermia. 2021;38(1):1092\u20131098","journal-title":"Int J Hyperthermia"},{"issue":"7","key":"11050_CR94","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s00330-017-5246-5","volume":"28","author":"AJ van der Molen","year":"2018","unstructured":"van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury\u2014part 1: definition, clinical features, incidence, role of contrast medium and risk factors\u202f: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018;28(7):2845\u20132855","journal-title":"Eur Radiol"},{"issue":"1","key":"11050_CR95","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1148\/radiol.2020202903","volume":"298","author":"JC Weinreb","year":"2021","unstructured":"Weinreb JC, Rodby RA, Yee J, et al. Use of intravenous gadolinium-based contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2021;298(1):28\u201335","journal-title":"Radiology"},{"issue":"9","key":"11050_CR96","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.ultrasmedbio.2006.05.031","volume":"32","author":"F Piscaglia","year":"2006","unstructured":"Piscaglia F, Bolondi L, Italian Society for Ultrasound in M, Biology Study Group on Ultrasound Contrast A. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol. 2006;32(9):1369\u20131375","journal-title":"Ultrasound Med Biol"},{"issue":"3","key":"11050_CR97","doi-asserted-by":"publisher","first-page":"531","DOI":"10.7863\/ultra.15.11075","volume":"36","author":"C Tang","year":"2017","unstructured":"Tang C, Fang K, Guo Y, et al. Safety of sulfur hexafluoride microbubbles in sonography of abdominal and superficial organs: retrospective analysis of 30,222 cases. J Ultrasound Med. 2017;36(3):531\u2013538","journal-title":"J Ultrasound Med"},{"issue":"2","key":"11050_CR98","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s13244-014-0315-7","volume":"5","author":"G Mauri","year":"2014","unstructured":"Mauri G, Porazzi E, Cova L, et al. Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment. Insights Imaging. 2014;5(2):209\u2013216","journal-title":"Insights Imaging"},{"issue":"8","key":"11050_CR99","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1007\/s00261-021-03059-y","volume":"46","author":"JR Eisenbrey","year":"2021","unstructured":"Eisenbrey JR, Gabriel H, Savsani E, Lyshchik A. Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies. Abdom Radiol (NY). 2021;46(8):3579\u20133595","journal-title":"Abdom Radiol (NY)"},{"issue":"3","key":"11050_CR100","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1148\/radiol.2018172743","volume":"288","author":"KD Song","year":"2018","unstructured":"Song KD, Lee MW, Rhim H, et al. Percutaneous US\/MRI fusion-guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma: technical feasibility and therapeutic outcomes. Radiology. 2018;288(3):878\u2013886","journal-title":"Radiology"},{"issue":"4","key":"11050_CR101","doi-asserted-by":"publisher","first-page":"227","DOI":"10.14366\/usg.14021","volume":"33","author":"MW Lee","year":"2014","unstructured":"Lee MW. Fusion imaging of real-time ultrasonography with CT or MRI for hepatic intervention. Ultrasonography. 2014;33(4):227\u2013239","journal-title":"Ultrasonography"},{"issue":"5","key":"11050_CR102","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1055\/a-2203-2733","volume":"196","author":"TJ Vogl","year":"2024","unstructured":"Vogl TJ, Martin SS, Gruber-Rouh T, et al. Comparison of microwave and radiofrequency ablation for the treatment of small- and medium-sized hepatocellular carcinomas in a prospective randomized trial. Rofo. 2024;196(5):482\u2013490","journal-title":"Rofo"},{"issue":"3","key":"11050_CR103","doi-asserted-by":"publisher","first-page":"562","DOI":"10.21037\/jgo.2019.01.34","volume":"10","author":"A Kamal","year":"2019","unstructured":"Kamal A, Elmoety AAA, Rostom YAM, Shater MS, Lashen SA. Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: a randomized controlled trial. J Gastrointest Oncol. 2019;10(3):562\u2013571","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"11050_CR104","volume":"16","author":"TM Shaqran","year":"2024","unstructured":"Shaqran TM, Alharbi J, Al-Hunbusi SK, et al. Comparison of radiofrequency ablation and microwave ablation for the management of hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2024;16(8): e67938","journal-title":"Cureus"},{"issue":"4","key":"11050_CR105","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.hpb.2020.08.006","volume":"23","author":"Y Feng","year":"2021","unstructured":"Feng Y, Wang L, Lv H, et al. Microwave ablation versus radiofrequency ablation for perivascular hepatocellular carcinoma: a propensity score analysis. HPB (Oxford). 2021;23(4):512\u2013519","journal-title":"HPB (Oxford)"},{"issue":"7","key":"11050_CR106","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1007\/s00330-020-07571-5","volume":"31","author":"C An","year":"2021","unstructured":"An C, Li WZ, Huang ZM, et al. Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis. Eur Radiol. 2021;31(7):4764\u20134773","journal-title":"Eur Radiol"},{"issue":"1","key":"11050_CR107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084484","volume":"9","author":"Y Wang","year":"2014","unstructured":"Wang Y, Luo Q, Li Y, Deng S, Wei S, Li X. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS ONE. 2014;9(1): e84484","journal-title":"PLoS ONE"},{"issue":"7","key":"11050_CR108","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1007\/s00330-020-07610-1","volume":"31","author":"P Gupta","year":"2021","unstructured":"Gupta P, Maralakunte M, Kumar MP, et al. Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC: a systematic review and Bayesian network meta-analysis. Eur Radiol. 2021;31(7):5400\u20135408","journal-title":"Eur Radiol"},{"issue":"1","key":"11050_CR109","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1148\/radiol.14132958","volume":"273","author":"M Ahmed","year":"2014","unstructured":"Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria\u2014a 10-year update. Radiology. 2014;273(1):241\u2013260","journal-title":"Radiology"},{"issue":"5","key":"11050_CR110","first-page":"317","volume":"3","author":"E Lahat","year":"2014","unstructured":"Lahat E, Eshkenazy R, Zendel A, et al. Complications after percutaneous ablation of liver tumors: a systematic review. Hepatobiliary Surg Nutr. 2014;3(5):317\u2013323","journal-title":"Hepatobiliary Surg Nutr"},{"key":"11050_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193251","author":"S Abu Zahra","year":"2025","unstructured":"Abu Zahra S, Nadeem A, Kundu A, et al. Recent advances in ablative therapies for hepatocellular carcinoma. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17193251","journal-title":"Cancers (Basel)"},{"issue":"10","key":"11050_CR112","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.14309\/ajg.0000000000002774","volume":"119","author":"QF Chen","year":"2024","unstructured":"Chen QF, Chen S, Yi JZ, et al. Recommended 10-year follow-up strategy for small hepatocellular carcinoma after radiofrequency ablation: a cost-effectiveness evaluation. Am J Gastroenterol. 2024;119(10):2052\u20132060","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"11050_CR113","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00262-020-02734-1","volume":"70","author":"K Leuchte","year":"2021","unstructured":"Leuchte K, Staib E, Thelen M, et al. Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2021;70(4):893\u2013907","journal-title":"Cancer Immunol Immunother"},{"key":"11050_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/ph16121672","author":"C Liao","year":"2023","unstructured":"Liao C, Zhang G, Huang R, et al. Inducing the abscopal effect in liver cancer treatment: the impact of microwave ablation power levels and PD-1 antibody therapy. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16121672","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"11050_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-025-02778-z","volume":"25","author":"GL Xie","year":"2025","unstructured":"Xie GL, Zhong ZH, Ye TW, Xiao ZQ. Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review. BMC Surg. 2025;25(1): 47","journal-title":"BMC Surg"},{"key":"11050_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.580241","volume":"10","author":"N Lyu","year":"2020","unstructured":"Lyu N, Kong Y, Li X, et al. Ablation reboots the response in advanced hepatocellular carcinoma with stable or atypical response during PD-1 therapy: a proof-of-concept study. Front Oncol. 2020;10: 580241","journal-title":"Front Oncol"},{"key":"11050_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.792781","volume":"12","author":"K Wang","year":"2021","unstructured":"Wang K, Wang C, Jiang H, et al. Combination of ablation and immunotherapy for hepatocellular carcinoma: where we are and where to go. Front Immunol. 2021;12: 792781","journal-title":"Front Immunol"},{"issue":"20","key":"11050_CR118","doi-asserted-by":"publisher","first-page":"20311","DOI":"10.1002\/cam4.6602","volume":"12","author":"Z Wen","year":"2023","unstructured":"Wen Z, Wang J, Tu B, et al. Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: a prospective controlled trial. Cancer Med. 2023;12(20):20311\u201320320","journal-title":"Cancer Med"},{"issue":"2","key":"11050_CR119","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1148\/radiol.2018171544","volume":"287","author":"AR Smolock","year":"2018","unstructured":"Smolock AR, Cristescu MM, Vlaisavljevich E, et al. Robotically assisted sonic therapy as a noninvasive nonthermal ablation modality: proof of concept in a porcine liver model. Radiology. 2018;287(2):485\u2013493","journal-title":"Radiology"},{"issue":"1","key":"11050_CR120","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/02656736.2022.2112309","volume":"39","author":"J Vidal-Jove","year":"2022","unstructured":"Vidal-Jove J, Serres X, Vlaisavljevich E, et al. First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study. Int J Hyperthermia. 2022;39(1):1115\u20131123","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"11050_CR121","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233051","volume":"312","author":"M Mendiratta-Lala","year":"2024","unstructured":"Mendiratta-Lala M, Wiggermann P, Pech M, et al. The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors. Radiology. 2024;312(3): e233051","journal-title":"Radiology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11050-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11050-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11050-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:01:50Z","timestamp":1777320110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11050-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["11050"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11050-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ching-Wei Chang, Ming Shun Wu, Wei-Yu Kao, Ming-Feng Chiang, Shih-Jer Hsu, Shen-Yung Wang, Chao-Hung Hung, Chih Horng Wu, San-Chi Chen, Yu-Ming Cheng, I-Cheng Lee, Yi-Chung Hsieh, Wei-Ting Chen, Chen-Chun Lin, Po-Chin Liang, Jen-I. Hwang, Shi-Ming Lin, Kai-Wen Huang, Chia-Yen Dai, Yi-Hsiang Huang, and Chia-Chi Wang have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}